Net profit of Biocon declined 56.74% to Rs 135.50 crore in the quarter ended March 2024 as against Rs 313.20 crore during the previous quarter ended March 2023. Sales rose 3.79% to Rs 3917.10 crore in the quarter ended March 2024 as against Rs 3773.90 crore during the previous quarter ended March 2023.For the full year,net profit rose 120.99% to Rs 1022.50 crore in the year ended March 2024 as against Rs 462.70 crore during the previous year ended March 2023. Sales rose 32.05% to Rs 14755.70 crore in the year ended March 2024 as against Rs 11174.20 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales3917.103773.90 4 14755.7011174.20 32 OPM %23.3125.36 -21.7820.98 - PBDT734.80863.30 -15 3105.602301.60 35 PBT327.80499.60 -34 1536.801188.50 29 NP135.50313.20 -57 1022.50462.70 121 Powered by Capital Market - Live News

Biocon announced that the Board of Directors of the Company at its meeting held on 16 May 2024, inter alia, have recommended the final dividend of Rs 0.5 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Biocon announced the signing of a semi-exclusive distribution and supply agreement with Medix, a specialty pharmaceutical company in Mexico, for the commercialization of its vertically integrated drug product, Liraglutide (gSaxenda), used in the treatment of chronic weight management. Under the terms of this agreement, Biocon will undertake the responsibility of obtaining regulatory approval, manufacturing and supply of the drug product, and Medix will be responsible for its commercialization in the Mexican market. Powered by Capital Market - Live News

Biocon will hold a meeting of the Board of Directors of the Company on 16 May 2024.Powered by Capital Market - Live News

Biocon has issued corporate guarantee of USD 20 million on behalf of Biocon Generics Inc, wholly owned step down subsidiary of the Company. The corporate guarantee valid for 5 years is for securing a term loan facility of USD 20 million from Mizuho Bank. Powered by Capital Market - Live News